The ADCY4 antibody is a research tool designed to detect adenylate cyclase 4 (ADCY4), a membrane-bound enzyme belonging to the adenylate cyclase family. ADCY4 catalyzes the conversion of ATP to cyclic AMP (cAMP), a critical secondary messenger regulating diverse cellular processes, including metabolism, gene expression, and cell signaling. Primarily expressed in the brain, heart, and lung tissues, ADCY4 is uniquely regulated by calcium/calmodulin signaling, distinguishing it from other isoforms. Its activity is linked to G protein-coupled receptor (GPCR) pathways, particularly those involving Gαs and Gαi subunits, which modulate cAMP levels in response to extracellular stimuli.
Research on ADCY4 has focused on its role in physiological and pathological conditions. Studies suggest its involvement in neurological disorders, cardiovascular diseases, and cancer, where dysregulated cAMP signaling contributes to disease progression. For example, ADCY4 mutations or altered expression have been implicated in bipolar disorder and heart failure. The ADCY4 antibody enables the detection and localization of ADCY4 in tissues or cultured cells, aiding investigations into its expression patterns, post-translational modifications, and interactions with regulatory proteins. It is commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Commercial ADCY4 antibodies are typically validated for specificity and sensitivity, though performance may vary between clones or hosts (e.g., rabbit, mouse). Ongoing research aims to clarify ADCY4's tissue-specific functions and therapeutic potential as a target for modulating cAMP-dependent pathways.